Reich K, Armstrong AW, Langley RG, et al. - In ECLIPSE, the first comparator study of an interleukin (IL)-23p19 inhibitor, guselkumab, vs an IL-17A inhibitor, secukinumab, researchers primarily compared the two treatment for superiority in the treatment response of moderate-to-severe psoriasis at week 48. This phase 3, multicentre, double-blind, randomized, comparator-controlled trial was conducted at 142 outpatient clinical sites in nine countries (Australia, Canada, Czech Republic, France, Germany, Hungary, Poland, Spain, and the USA). Eligible patients were those who were aged 18 years or older, had moderate-to-severe plaque-type psoriasis, and were candidates for phototherapy or systemic therapy. Eligible patients were randomly assigned to receive either guselkumab or secukinumab. Outcomes indicated superior long-term efficacy of guselkumab vs secukinumab for treating moderate-to-severe psoriasis based on Psoriasis Area and Severity Index (PASI 90 response) at week 48. This finding may assist in the decision-making process when selecting a biologic for treating moderate-to-severe psoriasis.